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Purpose. To determine the density variation between (1) the measured
density and manually calculated density, (2) density variation of different
lots, and (3) density variation of different drug manufacturers in order to
support institutions using gravimetric compounding methods.
Summary. Seventeen sterile injectable ingredient (drug) vials frequently
used to make compounded sterile products (CSPs) were identified based
on the ability to ensure that for each drug there were vials produced by 2
different manufacturers and 2 lots produced by the same manufacturer.
Each drug’s density was measured using a density meter and by manual calculation using the institution’s density formula. Density differences
were compared between the 2 different methods. Overall, the average
drug density difference between the measured versus calculated density
was determined to be 0.022. Further analysis revealed the average difference between the different lot numbers of the same manufacturers was
0.005 for the nonhazardous drugs and 0.0001 for the hazardous drugs.
The average difference between the different manufacturers of the same
drug was determined to be 0.008 for the nonhazardous drugs and 0.001
for hazardous drugs.
Conclusion. No clinically meaningful difference exists when manually calculating a drug’s density compared to measuring a drug’s density using a
density meter. In addition, there does not appear to be a sizeable density
variation between the same drugs in separate lots or produced by different
manufacturers.
Keywords: drug compounding, pharmaceutical preparations, specific
gravity
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he use of intravenous workflow
management systems (IVWMSs),
including those with capabilities for
gravimetric-based verification of compounded sterile products (CSPs), by
health-system pharmacies has increased
from 8% in 2014 to 36% in 2021.1 The
Institute for Safe Medication Practices
(ISMP) “Guidelines for Safe Preparation
of Compounded Sterile Preparations”
strongly encourage the use of
technology-assisted workflow, also
known as an IVWMS, with gravimetric
capabilities to produce CSPs.2 Studies
have shown that the use of gravimetric
IVWMSs has increased the error capture rate in preparation of nonhazardous
CSPs, leading to safer and more accurate
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products.3,4 Other studies comparing
gravimetric IVWMSs to a volumetricbased system in the compounding of
hazardous drugs have found that the use
of a gravimetric IVWMS produced more
accurate products.5-8
Gravimetric preparation assures
the correct volume and assesses syringe volume consistency and accurate
reconstitution. When using gravimetric
verification, the ordered dose is compared to the final syringe weight by
using a medication’s density. One can
use a manufacturer-reported specific
gravity or calculate the density from
the drug label information provided by
the manufacturer to the Food and Drug
Administration (FDA).9

VOLUME 79

|

NUMBER 8

|

April 15, 2022  689

Downloaded from https://academic.oup.com/ajhp/article/79/8/689/6432148 by Henry Ford Hospital - Sladen Library user on 13 May 2022

Lindsey B. Amerine, PharmD, MS,
BCPS, FASHP, UNC Health, Morrisville,
NC, and UNC Eshelman School of
Pharmacy, Chapel Hill, NC, USA

Descriptive Report

IMPACT OF DENSITY VARIATIONS ON STERILE COMPOUNDING

690

AM J HEALTH-SYST PHARM

|

KEY POINTS
• The use of manually calculated densities is an acceptable alternative to measuring
densities with a densitometer when using gravimetric
technique in pharmacy
compounding.
• Clinically insignificant differences were seen between
drug densities of the evaluated
samples of the same drug
produced in different lots or by
different manufacturers.
• The combination of this information could help lead to
a shared repository of drug
density data among institutions
to accelerate the use of gravimetric technique and increase
patient safety.

variation between different lot numbers and manufacturers of the same
drug. With this knowledge, institutions
can accurately build their drug density
database in order to successfully implement gravimetric-based IVWMS.
The purpose of this study is to
evaluate the density variability when
it is manually calculated versus measured directly using a density meter
while also comparing the lot and
manufacturer density variability of the
same drugs.

Study methodology
The study consisted of 2 separate
phases: a collection phase and a measurement phase. The collection phase
involved the selection and procurement of the study drugs from the primary wholesaler to the institution and
regional hospitals. The measurement
phase involved determining the density
of the included study drugs either by
using the density meter or by manual
calculation.
Collection protocol. In order
to determine the drugs used for
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measurement, a 1-year purchase history obtained from the primary wholesaler was analyzed. This yielded a list of
the top 200 ingredient vials used in routine practice.
Drugs from the top 200 list were
selected if they met the following
criteria:
•
•

Vial price of $20 or less
For each study drug, 2 different
manufacturers were available and
for each manufacturer, 2 different lot
numbers were available

Two different densities were collected
from the different manufacturers of
each drug, and 2 separate densities
were collected from the different lots
from each of the manufacturers. As a
result, there were 4 vials for each drug
within the study. A total of 17 drugs
that matched the selection criteria were
available to be purchased, representing
a total of 68 vials, representing 136
measurement samples in total (Table 1).
Measurement protocol. Drugs
were separated into hazardous and
nonhazardous drugs based on he
National Institute for Occupational
Safety and Health (NIOSH) list of hazardous drugs.11 The 17 drugs were
examined in the measurement phase.
The measurement phase consisted of
measuring each vial using the density
meter and manually calculating the
density, with both procedures performed according to existing institution
protocols described in Box 1 and Box 2,
respectively.
Density meter. For drugs requiring
reconstitution by the user, each drug was
reconstituted via gravimetric methods
using the institution’s gravimetricbased IVWMS (BD Pyxis IV Prep, v. 2.4;
Becton, Dickinson and Company, San
Diego, CA) according to institutional
instructions with either sterile water for
injection or 0.9% sodium chloride injection. Hazardous drug measurements
were done in an ISO class 5 environment within a biological safety cabinet.
Immediately after a drug was reconstituted, density measurements obtained
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Although incorporating gravimetricbased verification improves the
safety and accuracy of CSPs, several
challenges exist to implementing a
gravimetric-based system. One challenge with gravimetric analysis is the
limited availability of manufacturerreported densities for medications
used in CSPs.10 The accuracy of gravimetric compounding is improved
with densities that are more accurate.
The use of a density meter may financially deter institutions from the
use of gravimetric-based verification.
However, it is not known if the manually calculated density leads to variation in the gravimetric analysis when
compared to density directly measured
by a density meter.
Until the FDA requires manufacturers to report drug densities, institutions have to rely on IVWMS vendors
to create a density database or create
a database on their own, potentially
crowdsourcing with peers to obtain
all the necessary density information.
Currently, it is not known whether there
is clinically significant or insignificant
density variability in the same drugs
produced by different manufacturers or
in different lots produced by the same
manufacturer. During a gravimetric
IVWMS workflow, the system may rely
on one density for a given drug, which
would not take into account any difference between lots or manufacturers of
the same drug if clinically significant
differences exist. If the density variability is significant between different
lots or manufacturers of the same drug,
the specific lot number for each drug
and manufacturer would have to be
recorded when establishing a density
database. Such variances would significantly hinder the creation of such a
database, as institutions receive varying
products as the institution’s primary
wholesaler, availability of the drug, and
prices change.
To our knowledge, this is the first
study to compare the density variations
of commonly compounded drugs when
measured by a density meter versus
manual calculation of density, as well
as the first study to quantify the density

Descriptive Report

IMPACT OF DENSITY VARIATIONS ON STERILE COMPOUNDING

Table 1. Drugs Included in Analysis
Drug Name

Concentration,
mg/mLa

Manufacturer

NDC Number

Lot Number

100

West-Ward

00143-9503-01

1801124.1

Acetazolamide

100

West-Ward

00143-9503-01

1601237.1

Acetazolamide

100

Xgen

39822-0190-01

AJ3482

Acetazolamide

100

Xgen

39822-0190-01

AH8249

Azithromycin

100

Fresenius Kabi

63323-0398-10

6118550

Azithromycin

100

Fresenius Kabi

63323-0398-10

6118424

Azithromycin

100

Apotex Corp

60505-6076-04

MT611

Azithromycin

100

Apotex Corp

60505-6076-04

MT709

Cefazolin

330

Novaplus

00143-9262-01

186077.1

Cefazolin

330

Novaplus

00143-9262-01

177046.1

Cefazolin

330

West-Ward Pharmaceuticals

00143-9924-90

188024.1

Cefazolin

330

West-Ward Pharmaceuticals

00143-9924-90

186075.1

Cefoxitin

180

Fresenius Kabi

63323-0342-25

T65L

Cefoxitin

180

Fresenius Kabi

63323-0342-25

EE3V

Cefoxitin

180

WG CriticalCare

44567-0246-25

238C

Cefoxitin

180

WG CriticalCare

44567-0246-25

786J

Ceftriaxone

100

Hospira

00409-7332-11

HR3356

Ceftriaxone

100

Hospira

00409-7332-11

HU0230

Ceftriaxone

100

Sandoz

00781-3209-90

HK2095

Ceftriaxone

100

Sandoz

00781-3209-90

HK2103

Dexamethasone sodium phosphate

4

Fresenius Kabi USA

63323-0165-05

6115812

Dexamethasone sodium phosphate

4

Fresenius Kabi USA

63323-0165-02

6119642

Dexamethasone sodium phosphate

4

Mylan

67457-0423-00

7050833

Dexamethasone sodium phosphate

4

Mylan

67457-0423-00

7050832

Fludarabine

25

Sagent

25021-0242-02

31323090B

Fludarabine

25

Sagent

25021-0242-02

31323090B

Fludarabine

25

Fresenius Kabi

63323-0192-02

6119684

Fludarabine

25

Fresenius Kabi

63323-0192-02

6119685

Fluorouracil

50

Fresenius Kabi

63323-0117-10

6119092

Fluorouracil

50

Fresenius Kabi

63323-0117-10

6118877

Fluorouracil

50

Accord

16729-0276-03

PW03866

Fluorouracil

50

Accord

16729-0276-03

PX02705

Furosemide

10

Hospira

00409-6102-18

W39768

Furosemide

10

Hospira

00409-6102-18

W25774

Furosemide

10

Claris Lifescience

36000-0282-25

A0A0749

Furosemide

10

Claris Lifescience

36000-0282-25

A0B0186

Methotrexate

25

Teva

00703-3671-01

18B08PA

Methotrexate

25

Teva

00703-3671-01

17K22MA

Continued on next page
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Continued from previous page
Table 1. Drugs Included in Analysis
Concentration,
mg/mLa

Methotrexate

25

Methotrexate

25

Manufacturer

NDC Number

Lot Number

Hospira

61703-0350-37

F104437AA

Hospira

61703-0350-37

E114437AA

Norepinephrine bitartrate

1

Teva

00703-1153-01

31323263B

Norepinephrine bitartrate

1

Teva

00703-1153-01

31323347B

Norepinephrine bitartrate

1

Claris Lifescience

36000-0162-01

17367C

Norepinephrine bitartrate

1

Claris Lifescience

36000-0162-01

17348D

Olanzapine

5

American Regent

00517-0955-01

702600

Olanzapine

5

American Regent

00517-0955-01

804200

Olanzapine

5

Sandoz

00781-3159-72

NU812

Olanzapine

5

Sandoz

00781-3159-72

NU810

Ondansetron

2

West-Ward

00641-6078-01

037415

Ondansetron

2

West-Ward

00641-6078-01

117318

Ondansetron

2

Hospira

00409-4755-18

X11950

Ondansetron

2

Hospira

00409-4755-18

W71681

Paclitaxel

6

Hospira

61703-0342-50

E026865BA

Paclitaxel

6

Hospira

61703-0342-50

F026865AA

Paclitaxel

6

Fresenius Kabi

63323-0763-50

8780026A01

Fresenius Kabi

63323-0763-50

8780059A01

Potassium chloride

Paclitaxel

2 mEq/mL

6

Hospira

00409-6651-19

89-446-DK

Potassium chloride

2 mEq/mL

Hospira

00409-6651-19

90-460-DK

Potassium chloride

2 mEq/mL

APP Pharmaceuticals

63323-0965-20

6015562

Potassium chloride

2 mEq/mL

APP Pharmaceuticals

63323-0965-20

6017003

Vancomycin

50

Athenex

70860-0105-20

YV746

Vancomycin

50

Athenex

70860-0105-20

163708

Vancomycin

50

Hospira

00409-4332-01

841653A

Vancomycin

50

Hospira

00409-4332-01

781903A

Vecuronium

1

Sun Pharma Global

47335-0931-40

JKS0398A

Vecuronium

1

Sun Pharma Global

47335-0931-40

JKS0478A

Vecuronium

1

Teva

00703-2914-01

31324476B

Vecuronium

1

Teva

00703-2914-01

31324532B

All concentrations expressed as mg/mL unless otherwise indicated.

a

using a density meter (Mettler Toledo
DA-100M Density Meter; Mettler Toledo,
Columbus, OH) were collected. Density
measurements were examined using the
institution’s protocol (shown in Box 1).
Each vial’s density was measured twice
(to account for same-sample variances)
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using the density meter and, in some
instances, 3 times; where there was a
difference, the 2 or 3 values were averaged for the final analysis. Two different
densities were collected for the products
for different manufacturers of each drug,
and 2 separate densities were collected
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for the different lots of each of the manufacturers. In the end, there were 8 different density measurements of each
study drug.
Manual calculation of densities. The
density of each study drug was manually calculated according to institutional
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Drug Name
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Box 1. Institutional Protocol for Calculating Densities by Density Meter
1.
2.

protocol, as seen in Box 2. For manual
calculations the following formula for
density was used:
Total Ingredient Mass
(active + inactive)
+ Diluent Mass
Density =
Final Volume

Results
Density meter versus manual
calculation. A total of 17 drugs were
included within the study, as seen in
Table 1. Thirteen of the study drugs
were classified as nonhazardous and
4 were classified as hazardous. A total
of 68 density measurements were included in the analysis. The average difference between the density measured

using the density meter and the manually calculated density was determined
to be 0.0217. This equates to an average
difference of 1.66%.
Lot variation. For nonhazardous
drugs, the average difference between the different lot numbers of the
same manufacturer was determined
to be 0.0005. For hazardous drugs, the
average difference between the different lots of the same manufacturer
was determined to be 0.0001.
Manufacturer variation. For
nonhazardous drugs, the average difference between values for products
of different manufacturers of the same
drug was determined to be 0.0008. For
hazardous drugs, the average density
AM J HEALTH-SYST PHARM
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Discussion
This study is the first to our knowledge that compared measured
densities to manually calculated
densities in order to advance the practice of using gravimetric technique. Our
findings suggest that there was a clinically insignificant difference, as demonstrated by the minute difference in
a given drug’s density measured using
a density meter compared to values
measured using the formula. While
there is no known density variation that
would lead to inaccurate final compounded products, it is reasonable to
suggest that the average density difference of 0.0217 would not lead to clinically significant differences in patient
outcomes. With the knowledge gained
in our study, we believe that when a
manufacturer does not report a drug’s
density, an institution may use a manually calculated density when using
gravimetric technique to prepare a CSP.
Another barrier to the use of a density
meter is the requirement of training
staff on how to use the machine. Using
a calculated density when the manufacturer has not reported a density
will allow an institution to save money
by forgoing the initial cost of a density
meter as well as associated maintenance fees and drug waste associated
with use of the density meter. These
findings may allow more institutions
to confidently implement gravimetric
compounding workflow for as many
products as possible.
A common question that arises
when implementing gravimetric technique is if there is a density difference
in using the same drugs but with different lots, or the same drug with different manufacturers. When finding
a density with a density meter, there
could be differences between values
for the same drug and different manufacturers or even in different lots of
the same drug produced by the same
manufacturer. A difference amongst
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Place the drying tube in the opening of the pump box.
Insert one of the sample inlet/outlet tubes in the sample outlet and route its
other end to a waste beaker.
3. Turn on the instrument.
4. Rinse the measurement tube with a syringe containing 10 mLofethanol. Slide
the tube of the air pump over the sample inlet to dry the measurement tube. Do
this by pressing the PUMP key. An asterisk shows that the pump is active. The
instrument itself checks when the measurement tube is dry and then switches
off automatically.
5. Enter the temperature for which you plan to measure your sample. Do this by
pressing FUNC, then “arrow up” or “arrow down” repeatedly until “Function 1
Meas. Parameter” appears. Press ENTER. Use the arrows to set the temperature, then press ENTER to confirm.
6. Determine the factor of the measurement tube. Press the CALIB key. After the
instrument measures the density of air, “Set Water” will be displayed. Inject distilled, degassed water into the sample inlet using a syringe and press CALIB.
If the instrument correctly displays the density of water, return to initial position by pressing RESET. Correct densities of water at various temperatures
are listed on page 13 of the instrument manual. If the difference between the
measured and the listed value is greater than 0.001 g/cm3, check whether the
measurement tube is clean and repeat the calibration.
7. Press the FUNC key, then press “up” or “down” arrow repeatedly until “Function
0 Sample No. Clear” appears. Press ENTER. This sets the sample number for
the next measurement to 1.
8. Press RESET to obtain initial display.
9. Repeat step 4 and inject the sample using a syringe.
10. Press the MEAS key.
11. “Measurement” flashes until the value is stable, then the result flashes until you
press RESET.
12. Enter densities up to the thousandths place (eg, 1.001 g/mL).

difference between values for 2 different manufacturers of the same drug
was determined to be 0.001. Full data
can be seen in Appendix 1.
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Conclusion

Box 2. Institutional Protocol for Manually Calculating Densities
For drugs already in solution:
1.

For drugs to be reconstituted:
1.
2.

Multiply the volume of sterile water for injection (SWFI) to be added by 0.997
and add this mass in grams to the mass of the powder.
Divide this total mass (in grams) by the volume of SWFI used to reconstitute
(in mL).
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a gravimetric drug database, regardless
of lot number or drug manufacturer.
In order to ensure the accuracy of
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check of the manually entered density
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of using gravimetric methods is to improve patient safety through improved
accuracy, so ensuring the density is
entered correctly into the system is
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A limitation of this study is that
there is not a known density difference
that would yield clinically significant
results. However, based on the minute
differences in densities reported, it is
reasonable to predict there would not
be a difference in the final compounded
product when verification is performed
using a gravimetric technique.
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